It targets key signalling pathways in cancer by inhibiting vascular endothelial growth factor receptor (VEGFR)-dependent tumour angiogenesis, and epidermal growth factor receptor (EGFR), and rearranged during transfection (RET)-dependent tumour cell proliferation and survival [1], [2]. This evidence concerns the gene EGFR and cancer.